Net Net Stock Overview

Subscribe

To see hundreds more international net nets, consider subscribing

Overview

Forte Biosciences Inc
Healthcare
P/NCAV
0.67x
Ticker
FBRX
Exchange
NASDAQ
Country
United States
Close
0.74 $
Mkt Cap
23.3M $
EV
-13.8M $
NCAV Burn Rate
9.6%
Current Ratio
10.45
Debt/Equity
0.0
EV/REV
N/Ax
EV/EBIT
0.4x
EV/FCF
0.5x
Dilution
43.3% p.A
Total Net Income
-336.2M $
Cheapness
99.0%
Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases. The Company is advancing its product candidate, FB-102, which is a proprietary molecule with potentially broad autoimmune applications, including in such indications as graft-versus-host disease (GvHD), vitiligo, and alopecia areata (AA). The Company’s FB-102 program focuses on addressing key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and T cell subsets. It owns one United States patent for administering a combination of Gram-positive and Gram-negative bacteria along with metabolites for treatment of a wide variety of skin conditions. The Company’s subsidiaries include Forte Subsidiary, Inc., Forte Biosciences Emerald Limited, and Forte Biosciences Australia Pty Ltd.

Profitability

positive values --- Average negative values

Margins

--- Average

Valuation

positive values --- Average negative values

Dilution

--- Average